FiveBiotech_IUBIO0310

8/12/2019 FiveBiotech_IUBIO0310

http://slidepdf.com/reader/full/fivebiotechiubio0310 1/3

INVESTMENT U RESEARCH REPORT

Five Biotech Stocks With PotentialTo Be 10-Baggersby Marc Lichtenfeld, Healthcare Expert, Investment U

Dear Reader,

My name is Marc Lichtenfeld.

I’ve been making a very successful living for over 14 years researching under-the-radar companies

working on important innovations – first as a Senior Analyst at a highly respected Wall Street research

firm, and most recently as the founder and Director of Research for Access Research Group.The work we do here at Access is second to none.

It’s the very same level of research Wall Street’s biggest fund and money managers paid my firm

millions to uncover. Only instead of helping Wall Street fund managers get richer, Access is geared to the

everyday individual who feels they deserve a cut of the best action as well.

I’m talking about the kind of situations that can produce explosive profits: small innovative companies

leading the next wave in biotech, healthcare and technology.

Companies you’re never likely to hear about, except through us…

Companies the mainstream media or Wall Street never cover – until it’s too late and most of the “early-in” profits have already been made…

Small companies in those all-important “gathering” stages – with virtually unlimited upside potential

ahead of them…

At our recent Investment U 2010 conference, I revealed 5 such companies.

Your “fast response” report on these appears in the following pages.

You’ll be able to watch and hear my full audio/video presentation when the MP3 recordings are

available soon.

Until then, remember these are speculative plays with substantial risk. However, the upside could beimmense.

Marc Lichtenfeld

PS: Learn more about our programs at

http://www.oxfordclub.com/oxf-research/Access/ACC1209.php?pub=ACC&code=MACCL301

1

E . 19 9 9

&

Investment U 105 West Monument Street Baltimore, MD 21201 800.992.0205 www.investmentu.com


http://www.investmentu.com/


http://www.investmentu.com/



2

Biotech Potential 10-Bagger #1

Celldex Therapeutics (Nasdaq:CLDX)

CDX-110 for brain cancer – Phase II results due mid year

Previous phase II extended survival to 26 months vs 15 months standard of care (Temodar)

$82M cash on the balance sheet

Celldex’s CDX-110 is in phase IIb trials for a common and aggressive form of brain cancer, glioblastoma

multiforme.

In previous phase II trials, patients treated with CDX-110 had a median survival of 26 months, versus a

historical median survival of 15 months for patients on Temodar, the current standard of care.

New phase IIb data is expected in June.


Orchid Cellmark (Nasdaq: ORCH)

Backlog of 400,000 untested rape kits

Trades <1x sales and at 1x book value

Orchid Cellmark provides DNA testing services in forensics, rape and paternity markets.

There are currently about 400,000 untested rape kits in police evidence lockers around the country. The

Federal government is doling out millions of dollars to state and local police in order to process those kits.

Orchid trades at less than 1 times sales and at 1 times book value.

Biotech Potential 10-Bagger #3Liberator Medical Holdings (OTCBB: LBMH)

CEO is founder of Liberty Medical

New Medicare ruling reimburses 200 catheters per month, up from 4

10 to 1 return on advertising dollars

Liberator is run by founder Mark Libratore who was the founder and former CEO of Liberty Medical,

which he built into a $100 million a year business before selling it.

Liberator uses the same model in the direct to consumer home catheter market, which is exploding due

to a 2009 Medicare ruling which now reimburses patients for 200 catheters per month, up from 4.

Liberator is the dominant player in the industry and is grabbing market share each quarter.


Nabi Biopharmaceuticals (Nasdaq: NABI)

NicVax in phase III for smoking cessation

Chantix generated $1B in revenue despite nasty side effects



3

NicVax has fewer and much less severe side effects

Nabi has a shareholder friendly board of directors and management team, thanks to a group of activist

investors who fought for changes in 2006 and 2007.

The company’s phase III smoking cessation candidate NicVax is as effective as blockbuster drug

Chantix, but with less severe side effects.


Cytori Therapeutics (Nasdaq: CYTX)

Stem cell device approved in Europe and Asia

Clinical trial data in heart attack and heart disease patients due

Recent price weakness is buying opportunity

Cytori’s Celution System extracts stem cells from a patient’s own fat tissue and reintroduces them into

the body.

The procedure is far less invasive, faster and yields more stem cells than the traditional method of harvesting them from bone marrow.

Celution is approved in Europe and Asia for breast reconstruction after partial mastectomy. Data on

heart attack and chronic heart disease are due out in May.

Doctors in Europe and Asia are using Celution for their own experiments and trials and should be

publishing their findings in the near future.

About Marc Lichtenfeld

Marc Lichtenfeld is Senior Analyst for the White Cap Report and Investment U and a specialist in

biotechnology/healthcare.

After starting out as a trader at Carlin Equities, Marc moved onto the contrarian Avalon Research Group

as a Senior Analyst. He also obtained his NASD Series 86 & 87 licenses (required for all sell-side analysts).

At Weiss Research, he co-managed the Real Wealth Portfolio and beat the S&P 500 by 17% over a six

month period.

Marc joined the team following a successful spell as Senior Columnist at TheStreet.com. A contrarian

investor by nature, Marc loves to shoot holes in conventional thinking and take profits where nobody else is

looking.

He’s broken several major stories on biotech companies and his investment approach blends thoroughfundamental research with the timing tools of technical analysis.

Copyright © 2010 – present by Investment U | 1.800.992.0205 | 105 West Monument Street | Baltimore, MD 21201 Investment U Disclaimer : Nothing published by Investment U should be considered personalized investment advice. Although our employeesmay answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice. We expressly forbid our writersfrom having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investmentsrecommended by Investment U should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Documents

FiveBiotech_IUBIO0310